More on FATE
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $2.41 |
|
|||
| Open | $2.41 | ||||
| 52 Wk High | $4.76 | ||||
| 52 Wk Low | $1.46 | ||||
| Day High | $2.41 | ||||
| Day Low | $2.41 | ||||
| P/E | N/A | ||||
| EPS | $-1.91 | ||||
| Volume | 19,588 | ||||
- H.C. Wainwright Reiterates Buy Rating on Fate Therapeutics (FATE)
- Fate Therapeutics gets FDA clearance for FT839 CAR T-cell candidate
- Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate
- Form SCHEDULE 13G/A FATE THERAPEUTICS INC Filed by: BlackRock, Inc.
- Fate Therapeutics to present FT819 systemic sclerosis data at ISSCR
- Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting
- Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences
- Form 4 FATE THERAPEUTICS INC For: Jun 12 Filed by: Redmile Group, LLC
- Form 4 FATE THERAPEUTICS INC For: Jun 12 Filed by: Lee Michael Stewart
- Form 4 FATE THERAPEUTICS INC For: Jun 12 Filed by: Xu Yuan
Entities mentioned with FATE
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Jefferies & Co | View Related Stories »
- S3 | View Related Stories »
- 13G | View Related Stories »
- ARK | View Related Stories »
- Definitive Agreement | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Show More...
